Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD

Advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) are chronic conditions with significant associated morbidity and mortality. Patients experience substantial symptom burden that is frequently undertreated due to adverse medication side effects. This article reviews the available evidence for the use of medical marijuana to manage chronic pain, nausea/vomiting, anorexia/cachexia, and pruritus, all of which are frequently reported by patients with advanced chronic kidney disease or end-stage renal disease.

Topical Medical Cannabis: A New Treatment for Wound Pain-Three Cases of Pyoderma Gangrenosum

Pain associated with integumentary wounds is highly prevalent, yet it remains an area of significant unmet need within health care. Currently, systemically administered opioids are the mainstay of treatment. The ideal methods of pain relief for wound patients are modalities that are topical, lack systemic side effects, noninvasive, self-administered, and display rapid onset of analgesia. Extracts derived from the cannabis plant have been applied to wounds for thousands of years.

Making medicine; producing pleasure: A critical examination of medicinal cannabis policy and law in Victoria, Australia

Several jurisdictions around the world have introduced policies and laws allowing for the legal use of cannabis for therapeutic purposes. However, there has been little critical discussion of how the object of ‘medicinal cannabis’ is enacted in policy and practice. Informed by Carol Bacchi’s poststructuralist approach to policy analysis and the work of science and technology studies scholars, this paper seeks to problematise the object of ‘medicinal cannabis’ and examine how it is constituted through governing practices.